Exchange: NASDAQ·Updated 07:30 PM EDT
News
all
press releases
Here's Why You Should Retain Inogen Stock in Your Portfolio for Now
INGN's POC demand, new products and international growth support its outlook, while U.S. channel shifts and distributor timing pose risks.
Zacks
More News
Is IDXX Worth Buying as Growth Strength Meets a Premium Valuation?
IDEXX pairs resilient diagnostics growth, margin gains and expanding innovation with a premium valuation that supports a hold-or-wait stance.
Zacks
Inogen Cuts 2026 Revenue Outlook as U.S. Channel Pressure Persists
INGN cuts its 2026 revenue outlook as U.S. channel pressure weighs, while international growth, new products and cost control offer support.
Zacks
Should Investors Buy Inogen as Low Valuation Meets Execution Risk?
Inogen's steep sales-multiple discount, improving margins and firm international demand clash with U.S. sales and rental weakness.
Zacks
Inogen Q2 Earnings Beat Estimates, Sales Rise Y/Y, 2026 View Cut
INGN's Q2 revenues rise 3% as international sales climb 14.8%, but U.S. weakness led it to cut its 2026 revenue outlook.
Zacks
Inogen (INGN) Reports Q2 Loss, Tops Revenue Estimates
Inogen (INGN) delivered earnings and revenue surprises of +17.65% and +0.30%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Inogen Announces Second Quarter 2026 Financial Results
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended June 30, 2026. Our second quarter results demonstrate continued demand for our products and validate the...
Business Wire
Inogen to Report Second Quarter 2026 Financial Results on August 6, 2026
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report second quarter 2026 financial results after the market closes on Thursday, August 6, 2026. On the same day, the Company will host a...
Business Wire
Inogen Announces the Appointment of Andy Reding as Chief Operating Officer
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Andy Reding to the newly created role of Chief Operating Officer, effective Monday, July 6, 2026. Mr. Reding will be responsible for...
Business Wire
Here's Why You Should Retain Inogen Stock in Your Portfolio for Now
INGN's POC strength, expanding respiratory portfolio and international momentum support growth, though U.S. revenue pressure remains a key risk.
Zacks

Advertisement|Remove ads.